Scilex Holding (SCLX) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Scilex Holding (SCLX) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Gsk |
93,162,528.78 Bn |
93,162,523.82 Bn |
7.76 Bn |
14.49% |
| 2 |
Eli Lilly |
1,017.87 Bn |
1,012.58 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
575.51 Bn |
553.46 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
400.43 Bn |
391.08 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
294.19 Bn |
288.54 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
182.41 Bn |
170.37 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
150.97 Bn |
143.24 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
145.75 Bn |
132.97 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
113.35 Bn |
102.90 Bn |
8.07 Bn |
8.81% |
| 10 |
Scilex Holding |
57.99 Mn |
-91.94 Mn |
4.15 Mn |
-65.91% |
| Date | Value |
|---|
| Mar 31, 2026 |
-65.91% |
| Dec 31, 2025 |
-115.64% |
| Sep 30, 2025 |
-5,762.22% |
| Jun 30, 2025 |
-129.00% |
| Mar 31, 2025 |
-6.99% |
| Dec 31, 2024 |
28.25% |
| Sep 30, 2024 |
95.02% |
| Jun 30, 2024 |
-41.03% |
| Mar 31, 2024 |
20.73% |
| Dec 31, 2023 |
-19.66% |
| Sep 30, 2023 |
-510.09% |
| Jun 30, 2023 |
-49.39% |
| Mar 31, 2023 |
-236.36% |
| Dec 31, 2022 |
49.29% |
| Sep 30, 2022 |
7,736.60% |
| Jun 30, 2022 |
-10,688.09% |
| Mar 31, 2022 |
-6,173.72% |
| Dec 31, 2021 |
-561,796.51% |
| Sep 30, 2021 |
-32,791.59% |
| Jun 30, 2021 |
-3,206.98% |
